A WORLD LEADER IN WOUND CARE
URGO Group is engaged on day to day basis with patients, healthcare professionals and the general public.
The Group develops innovative wound dressings to address an increased need worldwide for the care of chronic wounds, and gives access to responsible healthcare solutions in the areas of first aid, nutritional supplements, sexual hygiene, cold and allergies.
About URGO Group
The mission of URGO group is wound healing, well-being and people’s health.
With its two divisions URGO Medical and URGO Consumer Healthcare, URGO Group is engaged on a day-to-day basis with patients, healthcare professionals and the general public. The Group develops innovative wound dressings to address an increased need worldwide for the care of chronic wounds, and gives access to responsible healthcare solutions in the areas of first aid, nutritional supplements, sexual hygiene, cold and allergies.
3,100 collaborators participate in these missions in 22 countries, among which 10 industrial production sites serve the needs of our clients.
URGO, which recorded a 662 million euros turnover (2016), developed a sound portfolio of very well-known brands such as Mercurochrome, Alvityl, Juvamine, Sonalto, Ricqlès, Urgo, all serving the Group’s global ambition.
To prepare for the future, UrgoTech, the group’s internal start-up, has the mission to explore and offer patients the benefits of connected health.
The Group’s engagement has always been to prevent and to heal. It turned innovation and production into strategic weapons to achieve that engagement, supported by its internal and partner-based research.
Get in touch with Urgo Group
Urgo Medical is the advanced wound care division of Urgo Group.
Because there is a burden of wounds around the world, our mission as the “Healing Company” is to alleviate patients’ suffering and heal wounds by providing the most appropriate dressings and protocols of care.
Urgo Medical is committed every day to working with healthcare professionals to help reduce healing time. Because each day without wounds makes a difference.
To make a difference for patients:
- We spend nearly 9% of our annual sales revenue on R&D programmes and public-private partnerships to advance scientific knowledge and treatments in advanced wound care.
- We demonstrate the clinical efficacy of our products with nearly 55 studies conducted and 40 scientific publications.
- We have a dynamic Medical Education policy with more than 35,000 healthcare professionals trained each year.
- We develop dedicated protocols of care (leg ulcer, diabetic foot ulcer) because we know that each type of wound needs a specific treatment.
- We have successfully developed a product portfolio adapted to each type of wounds with UrgoTul, UrgoStart, UrgoK2 et UrgoClean.
Today, we are convinced that the global improvement of the patient pathway will contribute to better wound care management. This is a major challenge for patients, health systems as well as healthcare professionals. And we believe that digital and e-health can play a major role in this transformation. This is why, beyond our products, we develop advanced solutions.
With more than 600 people spread over 7 countries, Urgo Medical achieved a turnover of 227 millions euros (+6,7%) in 2016 and is in the third place in the European advanced wound care market.